BRPI0600285A - compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas - Google Patents

compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas

Info

Publication number
BRPI0600285A
BRPI0600285A BRPI0600285-4A BRPI0600285A BRPI0600285A BR PI0600285 A BRPI0600285 A BR PI0600285A BR PI0600285 A BRPI0600285 A BR PI0600285A BR PI0600285 A BRPI0600285 A BR PI0600285A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compounds
compounds useful
nanoparticles
treating restenosis
nanoparticulate pharmaceutical
Prior art date
Application number
BRPI0600285-4A
Other languages
English (en)
Inventor
Alexandre Do Canto Zago
Alcides Jose Zago
Original Assignee
Brz Biotecnologia Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brz Biotecnologia Ltda filed Critical Brz Biotecnologia Ltda
Priority to BRC10600285-4A priority Critical patent/BRPI0600285C1/pt
Priority to EP07701600A priority patent/EP1978957A4/en
Priority to CA002636336A priority patent/CA2636336A1/en
Priority to JP2008549721A priority patent/JP2009523133A/ja
Priority to CNA2007800017443A priority patent/CN101365447A/zh
Priority to AU2007204550A priority patent/AU2007204550A1/en
Priority to PCT/BR2007/000015 priority patent/WO2007079560A2/en
Publication of BRPI0600285A publication Critical patent/BRPI0600285A/pt
Priority to US12/217,028 priority patent/US20090011005A1/en
Publication of BRPI0600285C1 publication Critical patent/BRPI0600285C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

COMPOSTOS FARMACêUTICOS CONTENDO NANOPARTìCULAS úTEIS PARA TRATAMENTO DE LESõES REESTENóTICAS São descritos compostos farmacêuticos contendo nanopartículas úteis para tratamento de lesões reestenóticas que compreendem nanoparticulas de rapamicina (sirolimus) ou análogos e/ou nanoparticulas de paclitaxel ou análogos, isoladamente ou em associação, ditas nanoparticulas com ou sem revestimento catiónico.
BRC10600285-4A 2006-01-13 2006-01-13 compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas BRPI0600285C1 (pt)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRC10600285-4A BRPI0600285C1 (pt) 2006-01-13 2006-01-13 compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
EP07701600A EP1978957A4 (en) 2006-01-13 2007-01-12 NANOTEILS CONTAINING PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF RESTENOTIC LESIONS
CA002636336A CA2636336A1 (en) 2006-01-13 2007-01-12 Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
JP2008549721A JP2009523133A (ja) 2006-01-13 2007-01-12 再狭窄病変治療に有用なナノ粒子含有の薬化合物類
CNA2007800017443A CN101365447A (zh) 2006-01-13 2007-01-12 用于治疗再狭窄病变的含有纳米粒子的药物组合物
AU2007204550A AU2007204550A1 (en) 2006-01-13 2007-01-12 Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
PCT/BR2007/000015 WO2007079560A2 (en) 2006-01-13 2007-01-12 Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
US12/217,028 US20090011005A1 (en) 2006-01-13 2008-07-01 Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRC10600285-4A BRPI0600285C1 (pt) 2006-01-13 2006-01-13 compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas

Publications (2)

Publication Number Publication Date
BRPI0600285A true BRPI0600285A (pt) 2007-10-02
BRPI0600285C1 BRPI0600285C1 (pt) 2011-10-11

Family

ID=38256650

Family Applications (1)

Application Number Title Priority Date Filing Date
BRC10600285-4A BRPI0600285C1 (pt) 2006-01-13 2006-01-13 compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas

Country Status (8)

Country Link
US (1) US20090011005A1 (pt)
EP (1) EP1978957A4 (pt)
JP (1) JP2009523133A (pt)
CN (1) CN101365447A (pt)
AU (1) AU2007204550A1 (pt)
BR (1) BRPI0600285C1 (pt)
CA (1) CA2636336A1 (pt)
WO (1) WO2007079560A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
EP2092942A1 (en) * 2006-11-20 2009-08-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
KR101314579B1 (ko) * 2011-04-07 2013-10-10 광주과학기술원 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CN114028623B (zh) * 2021-10-26 2024-02-27 江苏朴芃医疗科技有限公司 心脏分流器

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
TR200003435T2 (tr) * 1998-05-20 2001-03-21 The Liposome Company,Inc. Yeni parçacıklı formülasyonlar
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030065382A1 (en) * 2001-10-02 2003-04-03 Fischell Robert E. Means and method for the treatment of coronary artery obstructions
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
CN102697737B (zh) * 2003-04-03 2014-03-19 杰西.L.-S.奥 负载肿瘤靶向药物的颗粒
MXPA05012467A (es) * 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
US8043631B2 (en) * 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US7727554B2 (en) * 2004-12-21 2010-06-01 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Sustained-release nanoparticle compositions and methods for using the same
WO2006102378A2 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions

Also Published As

Publication number Publication date
JP2009523133A (ja) 2009-06-18
CN101365447A (zh) 2009-02-11
BRPI0600285C1 (pt) 2011-10-11
EP1978957A4 (en) 2013-01-09
WO2007079560A3 (en) 2007-12-27
AU2007204550A1 (en) 2007-07-19
US20090011005A1 (en) 2009-01-08
EP1978957A2 (en) 2008-10-15
WO2007079560A2 (en) 2007-07-19
CA2636336A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
BRPI0600285A (pt) compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
WO2007070666A3 (en) Anti-adhesion agents for drug coatings
PL2101792T3 (pl) Zastosowanie karageniny do leczenia zakażeń rinowirusem
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
BRPI0717822A2 (pt) Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
BR112022012266A2 (pt) Combinações
EP2134736A4 (en) FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER
WO2007109633A3 (en) Organotellurium and selenium-based antimicrobial antimicrobial formulations and articles
BRPI0816814A2 (pt) composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
TNSN08496A1 (en) Aminothiazoles and their uses
TWI369590B (en) Treatment liquid for resist substrate, and method of treating resist substrate using the same
BRPI0710964A2 (pt) método de tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular; composição farmacêutica; uso de composto na fabricação de um medicamento para o tratamento de lesão muscular, perda muscular, degeneração muscular, atrofia muscular ou taxa reduzida de reparo muscular
TN2009000495A1 (en) Macrocycles and their uses
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B11Q Dismissal: the certificate of addition was not accessory to any patent, or a patent which was nominated accessory and no longer exists

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: